Hematology/Oncology and Stem Cell Therapy

Targeting modulation of T-cell co-stimulation is one approach that aims to fight the cancer rather than targeting the tumor to eradicate the disease. This approach may enhance cells’ antitumor activity and potentially leads to a response that can last

  • Cancer immunotherapy is a rapidly emerging field supported by compelling single-agent data, and more recently, with very encouraging combination data
  • Immunotherapeutic approaches may provide improved, durable antitumor activity by amplifying and self-renewing immune response and utilizing long-term memory
  • Preclinical and early clinical studies indicate a potential to improve efficacy using combination approaches involving immunotherapeutic agents with differing modes of action
  • Immunotherapeutic agents could form the backbone of numerous potential combinations and indications in various lines of therapy
  • In silico drug discovery
  • Stem cells in drug discovery
  • Neural Diseases
  • Nanoparticles in drug delivery
  • Stem cells in drug discovery
  • Microbial derived drugs in drug discovery
  • Clinical biomarkers in drug discovery and development
  • Chemical biology approach to drug discovery

Related Conference of Hematology/Oncology and Stem Cell Therapy

Hematology/Oncology and Stem Cell Therapy Conference Speakers